title: Exploiting inflammation for therapeutic gain in pancreatic cancer.
abstract: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy associated with <5% 5-year survival, in which standard chemotherapeutics have limited benefit. The disease is associated with significant intra- and peritumoral inflammation and failure of protective immunosurveillance. Indeed, inflammatory signals are implicated in both tumour initiation and tumour progression. The major pathways regulating PDAC-associated inflammation are now being explored. Activation of leukocytes, and upregulation of cytokine and chemokine signalling pathways, both have been shown to modulate PDAC progression. Therefore, targeting inflammatory pathways may be of benefit as part of a multi-target approach to PDAC therapy. This review explores the pathways known to modulate inflammation at different stages of tumour development, drawing conclusions on their potential as therapeutic targets in PDAC.
authors: The Beatson Institute for Cancer Research, Glasgow G61 1BD, UK.
authors: C W
authors: CW
authors: Steele
authors: N B
authors: NB
authors: Jamieson
authors: T R J
authors: TR
authors: Evans
authors: C J
authors: CJ
authors: McKay
authors: O J
authors: OJ
authors: Sansom
authors: J P
authors: JP
authors: Morton
authors: C R
authors: CR
authors: Carter
mesh_terms: D000818:Animals; D021441:Carcinoma, Pancreatic Ductal / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D018925:Chemokines / Q000378:metabolism; D016207:Cytokines / Q000378:metabolism; D006801:Humans; D007157:Immunologic Surveillance; D007249:Inflammation / Q000628:therapy*; D008264:Macrophages / Q000276:immunology; D058990:Molecular Targeted Therapy; D009154:Mutation; D009362:Neoplasm Metastasis; D010190:Pancreatic Neoplasms / Q000235:genetics / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D011379:Prognosis; D015398:Signal Transduction; D019139:Tumor Escape; D059016:Tumor Microenvironment / Q000276:immunology
chemical_list: D018925:Chemokines; D016207:Cytokines
references: JAMA. 2010 Sep 8;304(10):1073-81
references: 20823433
references: Cancer Cell. 2012 Jun 12;21(6):822-35
references: 22698406
references: J Clin Invest. 2012 Nov;122(11):4118-29
references: 23023703
references: Cancer Discov. 2012 Mar;2(3):260-269
references: 22585996
references: Cancer Cell. 2012 Mar 20;21(3):418-29
references: 22439937
references: N Engl J Med. 1993 May 20;328(20):1433-7
references: 8479461
references: Clin Dev Immunol. 2010;2010:516768
references: 21048993
references: Gut. 2013 Feb;62(2):310-6
references: 21997559
references: Cancer Cell. 2011 Apr 12;19(4):441-55
references: 21481787
references: J Exp Med. 2012 Aug 27;209(9):1671-87
references: 22908323
references: Science. 2011 Mar 25;331(6024):1612-6
references: 21436454
references: J Clin Oncol. 2011 Dec 1;29(34):4548-54
references: 21969517
references: Cancer Biother Radiopharm. 2011 Aug;26(4):407-15
references: 21812653
references: J Immunol. 2005 Oct 1;175(7):4583-92
references: 16177103
references: Science. 2009 Jun 12;324(5933):1457-61
references: 19460966
references: Surgery. 1997 Jan;121(1):42-9
references: 9001550
references: Mol Cancer Res. 2009 May;7(5):624-33
references: 19435817
references: Cancer Cell. 2010 Nov 16;18(5):448-58
references: 21075310
references: J Clin Oncol. 2007 Jan 20;25(3):319-25
references: 17235047
references: Nat Rev Immunol. 2009 Mar;9(3):162-74
references: 19197294
references: Nature. 2011 Jul 06;475(7354):106-9
references: 21734707
references: Cell. 2012 Jan 20;148(1-2):21-3
references: 22265397
references: N Engl J Med. 2008 Jun 19;358(25):2704-15
references: 18565863
references: Cancer Cell. 2007 Mar;11(3):291-302
references: 17349585
references: Cancer Res. 2008 Mar 1;68(5):1443-50
references: 18316608
references: Mod Pathol. 2007 Feb;20 Suppl 1:S113-31
references: 17486047
references: Cancer Prev Res (Phila). 2010 Nov;3(11):1427-34
references: 20959520
references: Cancer Res. 1997 May 1;57(9):1731-4
references: 9135016
references: Genes Dev. 2006 May 15;20(10):1218-49
references: 16702400
references: Biochim Biophys Acta. 2011 Jan;1815(1):44-64
references: 20888394
references: Cancer Cell. 2012 Jun 12;21(6):836-47
references: 22698407
references: Cancer Cell. 2009 Sep 8;16(3):183-94
references: 19732719
references: Cancer Cell. 2012 Jan 17;21(1):105-20
references: 22264792
references: Lancet. 2011 Aug 13;378(9791):607-20
references: 21620466
references: Cell. 2012 Jan 20;148(1-2):349-61
references: 22265420
references: Cancer Res. 2011 Jul 15;71(14):5020-9
references: 21586612
references: Ann Surg. 2004 Jun;239(6):763-9; discussion 769-71
references: 15166955
references: Invest New Drugs. 2005 Dec;23(6):583-90
references: 16034525
references: J Clin Invest. 2012 Mar;122(3):787-95
references: 22378047
references: J Clin Invest. 2011 Oct;121(10):4106-17
references: 21926469
references: Cancer Res. 2007 Oct 1;67(19):9518-27
references: 17909062
references: Gut. 2011 Jun;60(6):861-8
references: 20966025
references: Cell. 2012 Jul 6;150(1):165-78
references: 22770218
references: J Am Coll Surg. 1999 Jul;189(1):1-7
references: 10401733
references: Cancer Cell. 2011 Apr 12;19(4):456-69
references: 21481788
references: Cancer Prev Res (Phila). 2011 Nov;4(11):1835-41
references: 21803981
references: Gut. 2013 Jan;62(1):112-20
references: 22466618
references: J Pathol. 2012 Jan;226(2):148-57
references: 21989643
references: Gastroenterology. 2011 Jan;140(1):310-21
references: 20955708
references: Cancer Res. 2007 Aug 1;67(15):7068-71
references: 17652141
references: Clin Cancer Res. 2000 Aug;6(8):2969-72
references: 10955772
references: Cancer Immunol Immunother. 2010 May;59(5):675-86
references: 19862523
references: J Exp Med. 2008 Jun 9;205(6):1261-8
references: 18490490
references: Am J Pathol. 2011 Mar;178(3):1340-9
references: 21356384